Health
Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform – News-Medical.Net
In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute…
In a groundbreaking bioRxiv* paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.
The ongoing coronavirus disease (COVID-19) pandemic is caused by the SARS-CoV-2,…
-
General23 hours agoByford rail extension opening marks final stage of Perth Metronet
-
General15 hours agoAustralia’s Diamonds defeat South Africa’s Proteas 65-42 in third netball Test
-
Noosa News20 hours agoSerious traffic crash, Noosa – Sunshine Coast
-
General16 hours agoThousands join pro-Palestinian rallies in towns and cities across Australia amid ceasefire